BCR and neoplasm: In contrast, it has been demonstrated that patients with CML possess T cells capable of recognizing autologous tumor cells, and clonally expanded T cells were identified in some TCR subfamilies in the peripheral blood of patients with CML, which display specific anti-leukemia cytotoxicity such as WT1 or BCR-ABL-specific cytotoxic T cells (CTLs), indicating that specific anti-leukemic T cells could be generated in vivo[13,16,17].